1. Home
  2. SBFM vs EAD Comparison

SBFM vs EAD Comparison

Compare SBFM & EAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SBFM
  • EAD
  • Stock Information
  • Founded
  • SBFM 2006
  • EAD 2003
  • Country
  • SBFM United States
  • EAD United States
  • Employees
  • SBFM N/A
  • EAD N/A
  • Industry
  • SBFM Biotechnology: Pharmaceutical Preparations
  • EAD Finance/Investors Services
  • Sector
  • SBFM Health Care
  • EAD Finance
  • Exchange
  • SBFM Nasdaq
  • EAD Nasdaq
  • Market Cap
  • SBFM 4.9M
  • EAD N/A
  • IPO Year
  • SBFM N/A
  • EAD N/A
  • Fundamental
  • Price
  • SBFM $1.51
  • EAD $6.66
  • Analyst Decision
  • SBFM Strong Buy
  • EAD
  • Analyst Count
  • SBFM 1
  • EAD 0
  • Target Price
  • SBFM $15.00
  • EAD N/A
  • AVG Volume (30 Days)
  • SBFM 4.3M
  • EAD 178.9K
  • Earning Date
  • SBFM 05-19-2025
  • EAD 01-01-0001
  • Dividend Yield
  • SBFM N/A
  • EAD 8.91%
  • EPS Growth
  • SBFM N/A
  • EAD N/A
  • EPS
  • SBFM N/A
  • EAD N/A
  • Revenue
  • SBFM $34,874,283.00
  • EAD N/A
  • Revenue This Year
  • SBFM $192.48
  • EAD N/A
  • Revenue Next Year
  • SBFM N/A
  • EAD N/A
  • P/E Ratio
  • SBFM N/A
  • EAD N/A
  • Revenue Growth
  • SBFM 44.75
  • EAD N/A
  • 52 Week Low
  • SBFM $1.17
  • EAD $5.69
  • 52 Week High
  • SBFM $33.60
  • EAD $6.81
  • Technical
  • Relative Strength Index (RSI)
  • SBFM 43.22
  • EAD 53.35
  • Support Level
  • SBFM $1.17
  • EAD $6.38
  • Resistance Level
  • SBFM $1.59
  • EAD $6.67
  • Average True Range (ATR)
  • SBFM 0.17
  • EAD 0.15
  • MACD
  • SBFM 0.04
  • EAD 0.04
  • Stochastic Oscillator
  • SBFM 70.89
  • EAD 98.72

About SBFM Sunshine Biopharma Inc.

Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.

Share on Social Networks: